Figure 1.

(A) Clone M3 primary tumor volumes. Tumors were implanted on Day 0 and ten days later when mean TV = 56.8 mm³ animals were randomized to five groups. IT LSAM-PTX (~60 mg/kg) was administered on Days 10, 14 and 18; IP anti-mPD-1 (10 mg/kg) was administered on Days 12, 15 and 18. Combination IT LSAM-PTX + IP anti-mPD-1 was administered at the same dose and schedules as the single treatments. IT vehicle + IP isotype control treatments were administered on the same schedule as the combination treatments. Untreated animals exhibited tumor growth consistent with previous studies. There were n= 8 animals/group throughout study with exception of the IT LSAM-PTX group with n=7 animals starting at Day 10 and the IT vehicle + IP isotype control group with n=7 animals starting at Day 19.; no other animals exited prior to Day 20. Data are group mean tumor volumes ± SEM. Treatment days are indicated as red triangles (LSAM-PTX) or blue diamonds (anti-mPD-1). (B) Clone M3 mean tumor volume (mm³) measured on Day 20 were significantly reduced in animals administered combination IT LSAM-PTX + IP anti-mPD-1 treatment compared to IT vehicle + IP isotype control animals. There were no other statistically significant differences between groups. Data are group mean tumor volumes + SEM; * = p < 0.05.